12:30 PM EDT, 04/07/2025 (MT Newswires) -- Eli Lilly ( LLY ) shares fell almost 4% in recent trading Monday after the Trump administration decided to table a plan allowing Medicare to pay for anti-obesity medications, which would have granted more people access to the company's weight-loss drug Zepbound.

The Centers for Medicare & Medicaid Services said Friday it was not finalizing the provision in the proposed rule at this time, but may address it in the future.

A Lilly spokesperson said Medicare's decision was not the best interpretation of the Part D Coverage provision of the rule and will impacts the access to obesity treatment.

"We will continue to work with the Trump Administration and Congressional leaders to ensure people living with obesity are covered by Medicare and Medicaid and are no longer left behind," the spokesperson said.

Price: 709.32, Change: -28.89, Percent Change: -3.91